Aardvark Therapeutics, Inc. (AARD)

In the past six months, Aardvark Therapeutics' stock price has experienced a significant range. As of March 27, 2026, the stock price was $3.55, with a 52-week range between $3.35 and $17.94. On February 12, 2026, Aardvark Therapeutics announced the establishment of Ardia Therapeutics, Inc., which can impact investor sentiment and stock price.

Aardvark Therapeutics is focused on developing novel therapeutics rather than commercializing approved products. Therefore, demand seasonality does not directly apply. The demand for its investigational drugs is driven by the progression of clinical trials, regulatory milestones, and the unmet medical needs they aim to address.

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics to treat metabolic diseases, particularly those involving hunger-associated conditions. Their lead product candidate is ARD-101, in Phase 3 clinical trials for hyperphagia associated with Prader-Willi Syndrome (PWS). They are also developing ARD-201 for obesity and related conditions, and DIA-615 for inflammatory skin diseases through their subsidiary, Ardia Therapeutics, Inc.

Aardvark Therapeutics is headquartered in San Diego, California, United States. Its operations center on research and development activities, including preclinical studies, clinical trials, regulatory strategy, and intellectual property management. The global nature of clinical trials suggests a broader geographic reach for research and potential commercialization efforts.

Information specifically detailing Aardvark Therapeutics' brand reputation was not explicitly found in the provided search results. Its reputation is likely closely tied to the progress and outcomes of its clinical trials, scientific publications, and corporate announcements.

Aardvark Therapeutics has both institutional and individual owners. Insider ownership transactions include share purchases by Tien-Li Lee and Nelson Sun in September 2025.